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Abstract Characterization of novel cell-surface protein mole-
cules, initially identified by cDNA cloning techniques, usually 
requires the generation of specific antibodies to further analyze 
their biochemical and/or functional properties. Here we report a 
simple method, using recombinant vaccinia virus, for the 
generation of monoclonal antibodies (mAb) to the cell-surface 
antigen endoglin. A recombinant vaccinia virus carrying a cDNA 
encoding human endoglin was inserted into the thymidine kinase 
locus under the control of the 7.5k vaccinia virus promoter. 
Infection of Balb/c mice with this recombinant virus led to the 
generation of specific polyclonal antibodies, as demonstrated by 
the antisera reactivity against human endoglin transfectants. The 
spleen cells of these infected animals were fused to myeloma 
cells, allowing efficient generation of several hybridomas which 
secrete mAbs to human endoglin, as evidenced by their reactivity 
with purified endoglin as well as with endoglin transfectants. 
Some of the mAbs selected seem to be specific for regions of 
endoglin conserved among different species as evidenced by their 
cross-reactivity with chicken endoglin. These results underline 
the utility of recombinant vaccinia virus to generate antibodies 
with novel properties to new cell surface proteins such as 
endoglin. 
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1. Introduction 
Monoclonal antibodies (mAb) specific to cell-surface anti-
gens have systematically provided a means of identifying and 
characterizing the structure and function of many integral 
membrane glycoproteins. The fast advances in molecular bi-
ology cloning have allowed the isolation of novel genes encod-
ing new membrane proteins. However, the initial character-
ization of these novel gene products is usually hampered by 
the lack of specific antibodies. To circumvent this problem 
some investigators have employed the approach of modifying 
the c D N A sequence by including a sequence tag within the 
coding region. Examples of these encoded tags include hexa-
histidine, influenza haemagglutinin (YPYDVPDYA) , vesicu-
lar stomatitis virus glycoprotein ( Y T D I E M N R L G K ) , and 
c-myc (EQKLISEEDL) peptides, which can be easily recog-
nized, within the corresponding fusion protein, by commer-
cially available antibodies. However, the utility of this tag 
method is exclusively restricted to the analysis of those cells 
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expressing the gene of interest by transfection. On the other 
hand, some authors have used direct immunization of the 
animals with c D N A [1,2], but the antibody titers of the cor-
responding sera are usually low. 
Based on the efficient immune response elicited upon infec-
tion with the vaccinia virus, the technology of constructing 
recombinant vaccinia viruses has opened up a new avenue 
to the production of safe and efficacious vaccines [3,4]. In 
terms of antibody response, the most successful antigens ex-
pressed from recombinant vaccinia viruses have been surface 
glycoproteins such as rabies G-protein, influenza haemagluti-
nin, or the rinderpest virus HN and F-proteins. Here, we have 
constructed a recombinant vaccinia virus expressing human 
endoglin, a surface component of the TGF-(3 receptor com-
plex [5]. Infection of Balb/c mice with this recombinant virus 
has allowed the efficient generation of hybridomas producing 
specific mAbs to endoglin. 
2. Materials and methods 
2.1. Recombinant vaccinia virus construction 
Culture of the Western reserve strain vaccinia virus and isolation of 
recombinant virus was performed as described [6]. Basically, plasmid 
pCEXV containing the L-isoform of human endoglin [7] was digested 
with EcoRl, and the resulting fragment was incubated with DNA 
polymerase I (Klenow fragment) and inserted into the Smal site of 
vaccinia virus plasmid pSCll . The resulting plasmid is a vector that 
coexpresses the CD105 gene inserted downstream of the 7.5k vaccinia 
virus promoter and the Escherichia coli ft-galactosidase gene under the 
control of the vaccinia virus I lk late promoter and flanked by viral 
thymidine kinase sequences. Thus, upon recombination in infected 
cells, both genes were inserted into the thymidine kinase locus of 
the vaccinia virus genome [8]. 
2.2. Generation and selection of mAbs to endoglin 
Balb/c mice were injected intraperitoneally with 107 pfu of either 
VV-L-Endo or VV-TK- in PBS on days - 3 0 and -14 . At day 0, 
animals were bled and spleen cells were fused with SP2 mouse mye-
loma cells at a ratio of 4:1 according to standard techniques [9]. 
Hybridoma culture supernatants were sequentially screened first by 
ELISA against purified endoglin coated to plastic, by flow cytometry 
analysis against rat myoblast transfectants expressing endoglin, and 
by Western blot analysis with purified endoglin. Hybridomas produc-
ing mAbs specific for endoglin were subjected to two rounds of clon-
ing by limiting dilution in flat-bottomed 96-well plates. 
2.3. ELISA 
Endoglin was purified by an immunoaffinity chromatography tech-
nique from human placenta as previously described for other cell 
surface glycoproteins [9,10]. Purified endoglin was diluted in 25 mM 
Tris-HCl, 150 mM NaCl, pH 8.2, at a final concentration of 10 ug/ml 
and 50 ul of this solution were incubated overnight at 4°C in each well 
of plastic 96-well flat-bottomed plates. Following saturation (2 h at 
room temperature) of the remaining free plastic sites with 200 ul of 
2% w/v bovine serum albumin in phosphate-buffered saline (PBS; 
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pH 7.4), wells were washed 3 times with PBS and incubated for 30 min 
at room temperature with 50 ul of the corresponding hybridoma 
culture supernatant. After three washes with PBS, 50 ul of a 1:1000 
dilution in RPMI medium of peroxidase-conjugated goat anti-mouse 
IgG (Sigma) were added to each well and incubated for 30 min. After 
three additional washes with PBS, 100 |xl of the peroxidase substrate 
o-phenylenediamine dissolved (0.12% w/v) in 0.2 M Na 2HP0 4 , 0.1 M 
citric acid buffer, pH 5, (0.12% w/v) and 0.108% v/v H 2 0 2 were added 
to each well and the reaction allowed to proceed until detectable 
yellow-brown colour is developed. Absorbance of each well at 
450 nm wavelength is finally measured in a SLT-Lab Instruments 
(Austria) ELISA reader. 
2.4. Flow cytometry 
L6E9 rat myoblast transfectants expressing human endoglin were 
generated as described [7]. For flow cytometry analyses, these cells or 
chicken fibroblasts (5 X 105) derived from primary cultures (a generous 
gift from Dr. J. Martin-Perez, IIB-CSIC, Madrid, Spain) were incu-
bated with the indicated antibodies for 30 min at 4°C in a flexiwell 
plate (Dynatech). After three washes with 200 ul of RPMI, FITC-
conjugated sheep anti-mouse IgG secondary antibody (Sigma) was 
added and incubation proceeded for an additional period of 30 min 
at 4°C. Finally, cells were washed twice with PBS and their fluores-
cence was estimated with a FACScan (Becton Dickinson), using log-
arithmic amplifiers. Antibodies used were from the indicated culture 
supernatants of hybridomas (anti-endoglin), or from sera of vaccinia 
infected mice at a 1:1000 dilution. Control mAbs used in this study 
were TS2/16 (anti-human CD29), X63 (negative control) and TEA 
1/62.2 (anti-human endoglin) [11]. 
2.5. Western blot analysis 
Purified endoglin from human placenta ( = 1 ug/lane) was subjected 
to SDS-PAGE on 7% polyacrylamide gels under non-reducing con-
ditions. Protein was electrophoretically transferred to nitrocellulose 
membranes using a semi-dry transfer cell (Bio-Rad). Filters were 
blocked with binding buffer (10 mM Tris-HCl, 100 mM NaCl, 0.2% 
Tween-20, pH 7.5), containing 5% non-fat dry milk for 2 h at room 
temperature. Specific immunodetection was carried out by incubation 
with the corresponding mAb in binding buffer 5% non-fat dry milk 
for 1 h at room temperature. After extensive washing in binding 
buffer, antibody binding to the membrane was detected with perox-
idase-conjugated goat anti-mouse antibody (Sigma). The presence of 
endoglin was revealed using a chemiluminescence assay (ECL detec-
tion kit, Amersham Iberica, Madrid, Spain). 
2.6. Immunoprecipitation analysis 
Human promonocytic U-937 cells were treated with 10 ng/ml of 
phorbol esters to overexpress endoglin as described [12]. Treated cells 
were iodinated with 0.5 mCi of 125I-labeled sodium iodine (ICN Bio-
medicals, Irvine, CA) using l,3,4,6-tetrachloro-3a,6a-diphenylglyco-
luril (Iodogen, Sigma, St. Louis, MO) and lysed in PBS containing 
1% Triton X-100, 1% BSA, 1 mM PMSF, 1 mM Ca2+, 1 mM Mg2+, 
pH 7.4, for 15 min. Lysates were immediately clarified by centrifuga-
tion at 700 Xg for 30 min and precleared with 30 ul of protein A-
Sepharose (Sigma). For immunoprecipitations, equal amounts of ra-
dioactive cell ly sates were incubated at 4°C with 100 ul of correspond-
ing hybridoma culture supernatants or 5 mg of purified mAb. After 
2 h, 100 ul of culture supernatant containing rat anti-mouse IgG mAb 
187.1 were added and incubation proceeded for an additional period 
of 2 h at 4°C. Finally, immunoprecipitates were removed by additions 
of 30 ul of protein A-Sepharose, incubation for 1 h with continuous 
stirring and centrifugation at 200 Xg. Samples were electrophoresed 
on SDS-7% polyacrylamide gels followed by exposure and analysis in 
a Molecular Imager System (GS-525, Bio-Rad). 
3. Results and discussion 
Endoglin is a surface component of the TGF-(3 receptor 
system expressed at high levels in endothelial cells [5,13,14]. 
The importance of endoglin in the biology of endothelial cells 
is demonstrated by the fact that mutations in the coding re-
gion of the endoglin gene are responsible for the disease 
known as hereditary haemorrhagic telangiectasia type 1 [15]. 
Expression of human endoglin can be achieved in vitro using 
recombinant vaccinia virus [8]. In order to facilitate functional 
studies on human endoglin we were interested in generating 
novel mAbs to human endoglin. To attain this, mice were 
infected with endoglin recombinant vaccinia virus and, to as-
sess the in vivo expression of human endoglin, the antibody 
specificity of their sera was analyzed by flow cytometry (Fig. 
1). VV-L-Endo-infected animals displayed a high positive titer 
of antibodies specific for endoglin compared with the negative 
response of W-TK-infected or naive animals, demonstrating 
the in vivo expression of endoglin upon infection with the 
recombinant virus. Next, spleen cells from these animals 
were fused to myeloma cells and the hybridoma culture super-
natants were screened by ELISA against endoglin-coated 
wells. We found that 18 out of 496 supernatants clearly rec-
ognized purified endoglin. Of these, 12 representative mAbs 
are shown in Table 1. Most of these mAbs also recognized 
endoglin expressed on the cell surface of mouse transfectants, 
as determined by flow cytometry (Table 1). Moreover, some 
of these mAbs were also able to recognize endoglin as deter-
mined by Western blot (Fig. 2A) and immunoprecipitation 
under non-reducing conditions (Fig. 2B) analyses, being the 
molecular mass of the protein recognized 180 kDa which is 
consistent with the published data. The specificity of these 
antibodies for endoglin was confirmed by their lack of reac-
tivity in Western blots against other purified proteins such as 
bovine serum albumin (BSA) or human purified pi integrin 
(not shown). Interestingly, some of these mAbs did show a 
specific cross-reactivity against chick (and rat) endoglin (Table 
2) which is an extremely useful feature that will permit the use 
of these antibodies to probe the functional relevance in vivo of 
endoglin in different animal models, such as the induction of 
angiogenesis in chick chorioallantoic membranes. 
Taken together, these results demonstrate that recombinant 
vaccinia virus can be used to generate mAbs to cell surface 
Table 1 
Screening of hybridoma supernatants specific for endoglin 
mAb 
X63 
TS2/16 
TEA1/62.2 
1B4 
1B5 
2E5 
2H6 
3A8 
4B2 
4D3 
4F9 
5A10 
5E5 
5H1 
5H11 
ELISAac 
0.17 
0.19 
0.72 
0.33 
0.62 
0.37 
0.61 
0.36 
0.49 
0.89 
0.37 
0.30 
0.41 
0.68 
0.41 
Flow cytometryb-c 
10.3 
13.6 
191.9 
104.1 
78.0 
48.2 
182.6 
91.5 
82.6 
241.0 
65.1 
30.2 
30.1 
79.5 
156.2 
aEndoglin-coated 96-well plates were incubated with the indicated 
hybridoma supernatants in duplicate. The bound mAb was estimated 
by using a goat anti-mouse IgG coupled to peroxidase and estimating 
the absorbance at 450 nm. Values correspond to one representative 
experiment out of three different ones. SD was always < 10%. 
bMyoblast transfectants expressing human endoglin were stained with 
the indicated hybridoma supernatants and analysed by flow cytome-
try. Values represent the mean channel fluorescence intensity ob-
tained. 
cCulture supernatants containing mAb TEA1/62.2 (anti-endoglin), 
TS2/16 (anti-pi integrin) or X63 (myeloma) were used as a positive 
and negative controls, respectively. 
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Fig. 1. Expression of recombinant endoglin in mice infected with re-
combinant vaccinia virus. Mice were immunized with recombinant 
vaccinia virus W-Endo or with control VV-TK- and sera was col-
lected and assayed by flow cytometry against rat myoblast transfec-
tants expressing L-endoglin. Sera from 12 different animals were 
found to specifically recognize human endoglin on the cell transfec-
tants. A representative experiment is shown. The reactivity of the 
sera from VV-TK" infected animals, used as a negative control, 
was similar to that obtained with sera from naive animals. 
glycoproteins like endoglin. This system takes advantage of 
the DNA recombinant techniques, allowing efficient immuni-
zation with the vaccinia virus containing the cDNA coding for 
the protein of interest. Other methods use naked DNA vac-
cines to generate specific antibody responses [1,2]. These DNA 
vaccines consist of plasmid DNA expression vectors that, 
when administered to an animal, result in the induction of 
antigen-specific immunity. Thus, the elicited immune response 
depends on the efficiency of the gene transfer process which is 
usually very low. This is in contrast with the broad infection 
of a natural mammalian host with vaccinia virus, whose effi-
ciency is only limited by lethality at very high doses. In our 
hands, relatively low doses of vaccinia were sufficient to im-
munize animals against the recombinant protein. Under these 
conditions, the vaccinia virus is cleared up from the circula-
tion in approximately 6-8 days upon infection [3] leaving the 
animal completely uninfected by the time of the cell fusion. 
This represents an advantage over the retroviral expression 
systems of surface antigens [16] as the retro virus is stably 
integrated into the cells of the infected animal. Finally, re-
combinant vaccinia virus can efficiently express endoglin in 
vitro at the surface of infected cells [8], allowing not only 
the immunization of the animals, but also the screening of 
specific hybridoma, in the absence of purified antigen. In sum-
Table 2 
Reactivity of hybridoma supernatants with endoglin expressed on 
chicken fibroblasts 
mAb Mean fluorescence intensitya,b 
X63 
TS2/16 
TEA1/62.2 
1B4 
2E5 
2H6 
3A8 
4B2 
4D3 
6.0 
6.8 
10.2 
132.8 
246.5 
12.0 
53.6 
8.4 
7.6 
aChicken fibroblasts were stained with the indicated hybridoma super-
natants and analysed by flow cytometry. Values represent the mean 
channel fluorescence intensity obtained. Culture supernatant contain-
ing mAb X63 (myeloma) was used as a negative control. 
Fig. 2. Characterization of mAb to endoglin. A: Western blot anal-
ysis. Purified endoglin from human placenta was subjected to SDS-
PAGE under non-reducing conditions and transferred to nitrocellu-
lose. Filters were incubated with the indicated mAb and the pres-
ence of endoglin was revealed using a chemiluminescence assay as 
a 180 kDa band. B: Immunoprecipitation analysis. PMA-treated, 
U-937 cells were 125I-labeled, lysed and immunoprecipitated with the 
indicated mAb. Samples were subjected to SDS-PAGE under non-
reducing conditions and specific bands detected with a Molecular 
Imager System. mAb TEA1/62.2 (anti-endoglin) and X63 were used 
as a positive and negative controls, respectively. The position of en-
doglin is indicated by an arrow head. 
mary, this report indicates that successful immunization with 
a recombinant vaccinia virus can be combined with the hy-
bridoma technology to yield specific mAbs with novel proper-
ties (cross-species reactivity) to a human cell surface antigen 
like endoglin. 
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